ZBIO
HealthcareZenas BioPharma, Inc.
$16.61
$-17.89 (-51.86%)
Jan 5, 2026
Price History (1Y)
Analysis
Zenas BioPharma, Inc. is a biotechnology company in the healthcare sector with a market capitalization of $891.61 million and 130 employees. The company's revenue totals $15.00 million. The financial health of Zenas BioPharma, Inc. is characterized by significant net losses, with a net income (TTM) of -$189,899,008 and an EBITDA of -$195,616,992. The company has a gross margin of 0.0%, operating margin of -1304.6%, and profit margin of 0.0%. Its return on equity is -68.3% and return on assets is -33.7%. Zenas BioPharma, Inc.'s balance sheet shows $290.88 million in cash and $798,000 in debt, resulting in a debt-to-equity ratio of 0.41 and a current ratio of 5.66. The valuation context for Zenas BioPharma, Inc. includes a price-to-earnings (P/E) ratio of 2.51, with a negative forward P/E of -4.37. The company's price-to-book ratio is 3.57 and its price-to-sales ratio is 59.44, while its EV/EBITDA is -7.98.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Zenas BioPharma, Inc.
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $891.61M
- P/E Ratio
- 2.51
- 52-Week High
- $44.60
- 52-Week Low
- $5.83
- Avg Volume
- 447.25K
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 130